Pasar al contenido principal

RECEPTORES MODULADORES DEL ESTADO INMUNOMETABOLICO DE CELULAS CON ACTIVIDAD ANTIVIRAL CONTRA EL VIH

PID2021-127899OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Combined dendritic cell and anti-TIGIT immunotherapy potentiates adaptive NK cells against HIV-1

  • Sánchez-Cerrillo, Ildefonso
  • Agudo-Lera, María
  • Popova, Olga
  • Tsukalov, Ilya
  • Calvet-Mirabent, Marta
  • de los Santos, Ignacio
  • García-Fraile, Lucio
  • Fuentes, Patricia
  • Delgado-Arévalo, Cristina
  • Alcain, Juan
  • Sánchez-Gaona, Nerea
  • Grau-Expósito, Judith
  • Lázaro-Díez, María
  • Muñoz-Calleja, Cecilia
  • Alfranca, Arantzazu
  • Genescà, Meritxell
  • Prado, Julia G.
  • Vrbanac, Vladimir
  • Balazs, Alejandro
  • Buzón, María José
  • Toribio, María L.
  • Muñoz-Fernández, María A.
  • Sánchez-Madrid, Francisco
  • Martín-Gayo, Enrique
Natural Killer (NK) cells are promising candidates for targeting persistently infected CD4 + T cells in people with HIV-1 (PWH). However, chronicity of HIV-1 infection impairs NK cell functionality, requiring additional strategies to potentiate their cytotoxic activity. This study demonstrates that dendritic cells primed with nanoparticles containing Poly I:C (Nano-PIC-MDDC) enhance the natural cytotoxic function of NK cells from effective responder PWH. These NK cells exhibit increased proportions of NKG2C+ cell subsets capable of eliminating HIV-1 infected CD4 + T cells through the TRAIL receptor. In contrast, in non-responder PWH, elevated expression of the inhibitory receptor TIGIT is associated with reduced frequencies of NKG2C + NK cells and diminished TRAIL expression. TIGIT blockade restores cytotoxicity of NK cells from non-responder PWH against HIV-1-infected cells by upregulating TRAIL. Furthermore, combining Nano-PIC-MDDC-primed NK cells with anti-TIGIT immunotherapy in humanized NSG mice reduces the expansion of HIV-1 infected cells, preserves NKG2C + NK cell precursors and increases TRAIL expression in tissue. Collectively, these findings support the combined use of Nano-PIC-MDDC and TIGIT blockade as a promising immunotherapeutic strategy toward an HIV-1 cure., EMG was supported by Ramón y Cajal Program (RYC2018-024374-I), the Spanish Agencia Estatal de Investigación RETOS, Generación de conocimiento and consolidation programs (RTI2018-097485-A-I00; PID2021-127899OB-I00; CNS2023-144841), La Caixa Banking Foundation ETI-CureHIV (HR20-00218), GLD24/00117 grant from Gilead Biosciences and infectious diseases CIBER (CIBERINFEC) from ISCIII (CB21/13/00107). MAL was supported by the Formación de Personal Investigador (FPI) grant PRE2022-104516. IT was supported by FPI UAM fellowship. CDA was supported by Comunidad de Madrid Talento Program (2017-T1/BMD-5396). MCM was supported by La Caixa Foundation ETI-CureHIV (HR20-00218). P2022/BMD7209-INTEGRAMUNE from Comunidad Autónoma de Madrid and La Caixa Health Research Grant LCF/PR/HR23/52430018 to and PID2023-149541OB-I00 FSM also supported the study. ISC was supported by infectious diseases CIBER from ISCIII (CB21/13/00107). JGP was supported by La Caixa Health program ETI-CureHIV project (HR20-00218), the CIBERINFECC from the National Health Institute Carlos III, and the project PI22/01120. MLT was supported by the Spanish Agencia Estatal de Investigación, Ministerio de Ciencia, Innovación y Universidades (PID2022-138880OB-I00 and PDC2021-121238-I00). NMC contributed to ROC Curve analysis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells

  • Martínez-Fleta, Pedro
  • Pertusa, Clara
  • Fernández-Delgado, Irene
  • Izquierdo-Serrano, Raúl
  • Ramírez-Huesca, Marta
  • Fernández-Gallego, Nieves
  • Calzada-Fraile, Diego
  • Moya-Ruiz, Elena
  • Castillo-González, Raquel
  • Guerra, Susana
  • Martín-Gayo, Enrique
  • Sánchez-Madrid, Francisco
The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15 mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15 BMDCs. Isg15 BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15 BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses., F.S.-M.’s laboratory is funded by the Spanish Ministry of Science and Innovation, Agencia Estatal de Investigación grants PID-2020-120412RB-I00, PID2023-149541OB-I00, “La Caixa” Foundation project code LCF/PR/HR23/52430018, P2022/BMD7209 (INTEGRAMUNE) funded by Comunidad de Madrid, and a grant from the Asociación Española Contra el Cáncer (AECC; PRYCO223002PEIN). E.M.-G. was supported by the Spanish Agencia Estatal de Investigación RETOS, Generación de conocimiento and consolidation programs (RTI2018-097485-A-I00;PID2021-127899OB-I00; CNS2023-144841), La Caixa Banking Fundation ETI-CureHIV(HR20-00218) and infectious diseases CIBER from ISCIII (CIBERINFEC) and a Gilead grant (GLD24/00117). R.C.-G. is supported by Ayudas para contratos Juan de la Cierva-formación 2021 (FJC2021-047282-I) from MICIN (Spain). P.M.-F. has been funded by a Rio-Hortega grant CM22/00076 from the Ministerio de Ciencia e Innovación (Instituto de Salud Carlos III) and co-funded by the European Regional Development Fund (ERDF) “A way to make Europe”. R.I.-S. was supported by a grant from the Spanish Agencia Estatal de Investigación (Ministerio de Ciencia e Innovación) (PRE2020-091912). E.M.-R. was supported by a grant from Comunidad de Madrid and co-funded by the European Regional Development Fund (ERDF) “A way to make Europe”. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dasatinib reversibly disrupts T cell motility and activation in lymph nodes

  • Carvoeiro, Daniela Claudino
  • Marcos-Jiménez, Ana
  • Tsukalov, Ilya
  • Viñas i Palou, Clara
  • Luquin, Sergio Sanchez
  • Eladnani, Ihssane
  • Hernanz, Raquel
  • Briones, Ana M.
  • Martín-Gayo, Enrique
  • Martín-Gayo, Enrique
  • Stein, Jens V.
The tyrosine kinase inhibitor dasatinib is prescribed as a first-line treatment for Philadelphia chromosome–positive leukemias and is increasingly used in other clinical settings. While dasatinib is effective and generally well tolerated, patients often experience a transient lymphocytosis attributable to a dasatinib-induced spleen contraction and an acute mobilization of splenocytes, as we have recently demonstrated in murine models and human patients. In contrast, the impact of dasatinib on lymphocyte surveillance of other secondary lymphoid organs, such as peripheral lymph nodes (LNs), has remained unclear. Here, we report that while dasatinib treatment selectively disrupted in vitro chemotaxis of B but not T cells, it caused a substantial, transient reduction of the in vivo interstitial motility in both subsets. The broad in vivo inhibition of T and B cell motility correlated with dasatinib-induced vasoconstriction of blood vessels and increased hypoxia within LNs. Pharmacological inhibition of the contraction-promoting factor Rho-associated coiled-coil kinase (ROCK) reversed dasatinib-induced LN hypoxia and rescued CD8 T cell motility. Last, dasatinib treatment delayed but did not inhibit dendritic cell–mediated CD8 T cell activation and proliferation within LNs. Overall, our findings uncover a dasatinib-induced transient disruption of the local adaptive immune system, which is distinct from the previously observed spleen contraction. From a clinical point of view, the disruption-recovery cycle of physiological immune surveillance induced by daily dasatinib treatment does not appear to cause a substantial impairment of key pathways underpinning CD8 T cell activation., This work was supported by the San Salvatore Foundation (J.V.S and C.M.-C.); Swiss National Foundation grants 31003A_172994, 310030_200406, and 320030-236044 (J.V.S.); Spanish Instituto de Investigación Carlos III (ISCIII) grant PI21/01803 (C.M.-C.); ISCIII grant JR23/00062 cofunded by European Social Fund, “Investing in your future” (A.M.-J.); The Spanish Agencia Estatal de Investigación Generación de Conocimiento and Consolidation programs PID2021-127899OB-I00 and CNS2023-144841 (E.M.-G.); Gilead Biosciences grant GLD24/00117 (E.M.-G.); Infectious Diseases CIBER from ISCIII (CIBERINFECC) (C.M.-C. and E.M.-G.).; Spanish Ministry of Science Innovation and Universities, Beca de Formación de Profesorado Universitario (FPU) (I.T.); and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033) and ERDF “A way of making Europe” grant PID2020-116498RB-I00 (A.M.B.).